Published in Neurology on November 01, 1993
What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry (2000) 4.66
Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology (2011) 1.68
Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology (2010) 1.53
Nursing home and end-of-life care in Parkinson disease. Neurology (2015) 1.48
Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol (2005) 1.14
Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry (2001) 1.14
Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13
Parkinson's disease dementia: a neural networks perspective. Brain (2015) 1.10
Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging (2008) 1.08
The natural history of Parkinson's disease. J Neurol (2006) 1.05
A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol (2008) 0.99
Late-stage Parkinson disease. Nat Rev Neurol (2012) 0.97
Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. J Neurol (2005) 0.96
Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res (2013) 0.95
The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry (2005) 0.94
Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol (2014) 0.89
The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease. Behav Neurol (2016) 0.89
Does clinical rapid eye movement behavior disorder predict worse outcomes in Parkinson's disease? J Neurol (2010) 0.89
Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry (1998) 0.88
Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol (2005) 0.88
Admission of Parkinsonian patients to a neurological ward in a community hospital. J Neural Transm (Vienna) (2009) 0.88
Neuropsychiatric symptoms in Parkinson's disease dementia are associated with increased caregiver burden. J Mov Disord (2015) 0.85
Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol (2011) 0.85
Psychosis in Parkinson's disease. Postgrad Med J (2005) 0.84
Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry (2007) 0.84
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health (2016) 0.84
Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. Trials (2014) 0.83
Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. JAMA Neurol (2016) 0.82
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. PLoS One (2014) 0.81
Non-Motor symptoms in Portuguese Parkinson's Disease patients: correlation and impact on Quality of Life and Activities of Daily Living. Sci Rep (2016) 0.80
The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol (2005) 0.79
Power spectra for screening parkinsonian patients for mild cognitive impairment. Ann Clin Transl Neurol (2014) 0.79
Treatment of advanced Parkinson's disease. Parkinsons Dis (2011) 0.79
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochem Res (2014) 0.78
Thought disorders among non-demented outpatients with Parkinson's disease: prevalence and associated factors. J Neural Transm (Vienna) (2010) 0.78
The quality of care delivered to Parkinson's disease patients in the U.S. Pacific Northwest Veterans Health System. BMC Neurol (2006) 0.78
Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? CNS Spectr (2008) 0.77
Psychosis in Parkinson's disease: identification, prevention and treatment. J Neural Transm (Vienna) (2015) 0.77
Parkinson's psychosis. Curr Treat Options Neurol (2010) 0.77
Lewy body dementia and Parkinson's disease with dementia. J Neurol (2008) 0.76
New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis (2011) 0.76
Management of non-motor complications in Parkinson's disease. J Neurol (2009) 0.75
Visual dysfunction in Parkinson's disease. Brain (2016) 0.75
Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis. Ther Adv Neurol Disord (2016) 0.75
Update on the treatment of Parkinson's disease psychosis: role of pimavanserin. Neuropsychiatr Dis Treat (2017) 0.75
Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson's Disease Patients. Front Neurol (2015) 0.75
Neuropsychiatric symptoms in an inpatient Parkinson's disease sample. Parkinsons Dis (2014) 0.75
Preferences and concerns for care needs in advanced Parkinson's disease: A qualitative study of couples. J Clin Nurs (2016) 0.75
Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. J Neurol Neurosurg Psychiatry (2017) 0.75
Evaluation and management of the non-motor features of Parkinson's disease. Ther Adv Chronic Dis (2011) 0.75
Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease. Mov Disord Clin Pract (2017) 0.75
Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord (1994) 2.77
Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol (2001) 2.51
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology (1994) 2.02
Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology (1998) 1.95
Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol (2013) 1.61
Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology (1998) 1.58
Risk factors for progression in Parkinson's disease. Neurology (1988) 1.49
Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology (1995) 1.46
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord (1996) 1.46
Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov Disord (1997) 1.32
Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord (1997) 1.23
Intact mirror-tracing and impaired rotary-pursuit skill learning in patients with Huntington's disease: evidence for dissociable memory systems in skill learning. Neuropsychology (1997) 1.15
Objective changes in motor function during placebo treatment in PD. Neurology (2000) 1.12
Cessation of driving and unsafe motor vehicle operation by dementia patients. Arch Intern Med (1991) 1.10
Adult tics in Gilles de la Tourette's syndrome: description and risk factors. Neurology (1992) 1.09
Working and strategic memory deficits in schizophrenia. Neuropsychology (1998) 1.05
Changes in parahippocampal white matter integrity in amnestic mild cognitive impairment: a diffusion tensor imaging study. Behav Neurol (2009) 1.04
Age-associated reduction of asymmetry in prefrontal function and preservation of conceptual repetition priming. Neuroimage (2008) 1.02
Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology (1999) 1.00
Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord (2000) 0.99
Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology (1998) 0.97
Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology (1996) 0.95
Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology (1992) 0.95
Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord (2000) 0.91
Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol (2001) 0.89
Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology (1990) 0.89
Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord (1990) 0.86
Neuropsychological dissociation between recognition familiarity and perceptual priming in visual long-term memory. Cortex (1998) 0.86
5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. Eur J Pharmacol (1998) 0.84
Age-related changes in parahippocampal white matter integrity: a diffusion tensor imaging study. Neuropsychologia (2012) 0.83
Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol (2014) 0.83
Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: two-year follow-up study. Exp Neurol (1997) 0.82
Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. Arch Neurol (1990) 0.82
Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol (1993) 0.82
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology (1993) 0.81
United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology (1991) 0.80
The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Mov Disord (1998) 0.78
Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial. Mov Disord (1994) 0.78
The effects of cerebral white matter changes on cardiovascular responses to cognitive and physical activity in a stroke population. Psychophysiology (2012) 0.77
Plasma L-tryptophan/neutral amino acid ratio and dexamethasone suppression in depression. Psychiatry Res (1984) 0.76
Psychotic symptoms in Parkinson's disease. J Am Geriatr Soc (1997) 0.75
United Parkinson Foundation Neurotransplantation Registry: multicenter US and Canadian data base, presurgical and 12 month follow-up. Prog Brain Res (1990) 0.75
Multiple sclerosis: an unexpected cause of senile dementia. Arch Neurol (1989) 0.75
The stability of carbidopa in solution. Mov Disord (1997) 0.75
Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise. Neurology (1993) 0.75
Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology (1996) 0.75
Effects of head trauma from motor vehicle accidents on Parkinson's disease. Ann Neurol (1991) 0.75
Cognitive assessment in Alzheimer's disease: cross-sectional and longitudinal perspectives. Can J Neurol Sci (1986) 0.75